WSJ Article Comparing Sarepta (SRPT) and BioMarin (BMRN) 'Juvenile and Uninformed', Roth Capital Says

Roth Capital analyst Debjit Chattopadhyay is taking exception to the bearish article published in the WSJ about Sarepta Therapeutic (NASDAQ: SRPT) which compared the company to its mature peer BioMarin (NASDAQ: BMRN) on a 2016 price/sales metric. The analyst said the article was "both juvenile and uninformed,"

"We are cognizant of the risk of recommending Sarepta shares heading into 2H15, but believe Sarepta is now significantly well positioned and has a better drug than BMRN, and do not expect an RTF," Chattopadhyay

The analyst notes that unlike BMRN, Sarepta has already initiated multiple confirmatory studies.

Further, he said it is highly unlikely that the FDA would have asked SRPT to proceed with the filing only to hand it an RTF in 60 days.

For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.

Shares of Sarepta Therapeutic closed at $26.24 yesterday.

You May Also Be Interested In

• Jefferies Upgrades Husqvarna AB (HUSQB:SS) to Buy
• First Cash Financial (FCFS) PT Lowered to $140 at TD Cowen
• AZZ, Inc. (AZZ) Announces Proposed 4M Share Offering